Ancora Advisors LLC Sells 80,000 Shares of Omeros Corporation $OMER

Ancora Advisors LLC decreased its holdings in Omeros Corporation (NASDAQ:OMER - Free Report) by 93.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,800 shares of the biopharmaceutical company's stock after selling 80,000 shares during the period. Ancora Advisors LLC's holdings in Omeros were worth $48,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Omeros by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company's stock valued at $314,000 after purchasing an additional 1,110 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after buying an additional 1,972 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Omeros by 4.9% in the 1st quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company's stock valued at $345,000 after buying an additional 1,973 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Omeros by 2.0% in the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company's stock valued at $1,190,000 after buying an additional 2,317 shares in the last quarter. Finally, Brighton Jones LLC grew its stake in shares of Omeros by 11.3% in the 1st quarter. Brighton Jones LLC now owns 30,714 shares of the biopharmaceutical company's stock valued at $252,000 after buying an additional 3,125 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. D. Boral Capital reaffirmed a "buy" rating and set a $36.00 target price on shares of Omeros in a research report on Wednesday, September 3rd. Wall Street Zen cut Omeros from a "hold" rating to a "sell" rating in a research report on Friday, June 27th. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research report on Friday, August 15th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Omeros in a research report on Friday, June 27th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.

Omeros Price Performance

Shares of NASDAQ:OMER traded down $0.06 during midday trading on Friday, reaching $4.15. The company's stock had a trading volume of 171,476 shares, compared to its average volume of 896,096. Omeros Corporation has a fifty-two week low of $2.95 and a fifty-two week high of $13.60. The company has a market capitalization of $282.11 million, a P/E ratio of -1.96 and a beta of 2.37. The business's fifty day simple moving average is $3.95 and its 200-day simple moving average is $5.18.

Omeros (NASDAQ:OMER - Get Free Report) last announced its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.02. The business had revenue of $28.60 million during the quarter, compared to analyst estimates of $0.31 million. On average, analysts forecast that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.